Efavirenz Use During Pregnancy and for Women of Child-Bearing Potential
Author Information
Author(s): Chersich Matthew F, Urban Michael F, Venter Francois WD, Wessels Tina, Krause Amanda, Gray Glenda E, Luchters Stanley, Viljoen Dennis L
Primary Institution: International Centre for Reproductive Health, Mombasa, Kenya
Hypothesis
What are the implications of efavirenz teratogenicity for women of childbearing potential?
Conclusion
Current recommendations for care for women who become pregnant while receiving efavirenz may need to be reconsidered, particularly in settings with limited alternative drugs.
Supporting Evidence
- Four retrospective cases of CNS birth defects were reported in infants with first trimester exposure to efavirenz.
- In a prospective pregnancy registry, no increase in overall risk of birth defects was detected following first-trimester exposure to efavirenz.
- WHO guidelines suggest that benefits of efavirenz likely outweigh risks for women using contraception.
- Current data limitations indicate a need for additional adequately powered prospective studies.
Takeaway
Efavirenz is a medicine that helps treat HIV, but it might cause problems for babies if taken during pregnancy. Doctors need to think carefully about when to use it.
Methodology
The study reviews evidence of efavirenz teratogenicity through retrospective case reports and a prospective pregnancy registry.
Potential Biases
Potential biases exist due to the retrospective nature of some data and the non-standardized ascertainment of birth defects.
Limitations
The study's findings are limited by the low enrollment rate in the pregnancy registry and the variability in reporting birth defects.
Participant Demographics
The study focuses on women of childbearing potential receiving antiretroviral treatment.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI: 0.7%-5.1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website